Reuters logo
4 个月内
BRIEF-Lilly says phase 3 breast cancer study meets primary endpoint
2017年3月20日 / 中午12点04分 / 4 个月内

BRIEF-Lilly says phase 3 breast cancer study meets primary endpoint

1 分钟阅读

March 20 (Reuters) - Eli Lilly And Co

* Lilly announces phase 3 monarch 2 breast cancer study of abemaciclib met primary endpoint of progression-free survival

* Eli Lilly And Co - its monarch 2 trial of abemaciclib met primary endpoint of progression-free survival (pfs)

* Eli Lilly And Co- intends to submit a new drug application (nda) for single-agent abemaciclib in q2 of 2017

* Plans to submit an additional application for monarch 2 in q3 of this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below